Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Painful physical symptoms and treatment outcome in major depressive disorder: a STAR*D (Sequenced Treatment Alternatives to Relieve Depression) report.

Tytuł:
Painful physical symptoms and treatment outcome in major depressive disorder: a STAR*D (Sequenced Treatment Alternatives to Relieve Depression) report.
Autorzy:
Leuchter AF; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024-1759, USA. />Husain MM
Cook IA
Trivedi MH
Wisniewski SR
Gilmer WS
Luther JF
Fava M
Rush AJ
Źródło:
Psychological medicine [Psychol Med] 2010 Feb; Vol. 40 (2), pp. 239-51. Date of Electronic Publication: 2009 Jun 03.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural
Język:
English
Imprint Name(s):
Publication: London : Cambridge University Press
Original Publication: London, British Medical Assn.
MeSH Terms:
Antidepressive Agents/*therapeutic use
Citalopram/*therapeutic use
Depression/*drug therapy
Depression/*epidemiology
Pain/*epidemiology
Pain/*physiopathology
Somatoform Disorders/*epidemiology
Somatoform Disorders/*physiopathology
Adolescent ; Adult ; Aged ; Cost of Illness ; Depression/diagnosis ; Drug Administration Schedule ; Female ; Humans ; Male ; Middle Aged ; Pain/diagnosis ; Pain Measurement ; Remission Induction ; Severity of Illness Index ; Socioeconomic Factors ; Somatoform Disorders/diagnosis ; Treatment Outcome ; Young Adult
Grant Information:
N01MH90003 United States MH NIMH NIH HHS
Molecular Sequence:
ClinicalTrials.gov NCT00021528
Substance Nomenclature:
0 (Antidepressive Agents)
0DHU5B8D6V (Citalopram)
Entry Date(s):
Date Created: 20090605 Date Completed: 20100319 Latest Revision: 20131121
Update Code:
20240104
DOI:
10.1017/S0033291709006035
PMID:
19493369
Czasopismo naukowe
Background: Painful physical symptoms (PPS) are both common and reduce the likelihood of remission in major depressive disorder (MDD), based upon results of clinical trials in selected populations. Whether PPS significantly contribute to poorer treatment outcome overall in primary or specialty psychiatric care settings remains unclear.
Method: Out-patients (n=2876) with MDD were treated in the first step of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial with citalopram up to 60 mg/day for up to 14 weeks. Presence of painful symptoms, as well as severity of depression, physical illness, and demographic and treatment factors were examined. Time to and overall rates of remission were analysed in relation to the presence of PPS.
Results: Of the participants, 80% complained of PPS. These patients, both in primary and specialty psychiatric settings, had significantly lower remission rates and took longer to remit. Increasing severity of PPS was associated with greater physical illness burden, lower socio-economic status, absence of private insurance and being female, African-American or Hispanic. After adjustment for these factors, patients with PPS no longer had significantly poorer treatment outcomes.
Conclusions: Presence and severity of PPS is an indicator of MDD that may have poorer treatment outcome with an initial selective serotonin reuptake inhibitor. These poorer treatment outcomes are multifactorial, however, and are not explained by the presence and severity of pain per se.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies